193739-32-1

Usage

Uses

Used in Pharmaceutical Applications:
(±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile is used as a pharmaceutical agent for its potential therapeutic properties. Its complex structure and functional groups may contribute to its efficacy in treating various medical conditions, although further research is needed to fully understand its pharmacological profile.
Used in Organic Synthesis:
In the field of organic synthesis, (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile serves as a valuable chemical intermediate. Its unique structure allows for the synthesis of other complex organic compounds, making it a useful building block in the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
(±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile is also utilized in medicinal chemistry research to explore its potential as a lead compound for the development of new drugs. Its diverse functional groups and structural features provide a foundation for further optimization and modification to enhance its pharmacological properties and therapeutic potential.
Used in Chemical Intermediates Industry:
(±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile is used as a key intermediate in the synthesis of various specialty chemicals. Its unique structure and functional groups make it an essential component in the production of advanced materials, dyes, and other chemical products that require complex molecular architectures.

Upstream product

• 205654-33-7 Trans-2-(3-Methoxy-4-p-chlorophenylthioethoxy-5-iodophenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 245469-66-3 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)butane-1,4-dione 
• 245469-67-4 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)-1,4-butanediol 
• 245469-62-9 3-(N,N-dimethylamino)-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]propan-1-one 
• 245469-65-2 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-en-1-one 
• 245469-59-4 ethanone-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl] 
• 245469-58-3 ethanone-1-[3-methoxy-4-(2-bromoethoxy)-5-iodophenyl] 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 103440-59-1 1-(4-hydroxy-3-iodo-5-methoxy-phenyl)ethan-1-one 
• 544-92-3 copper(I) cyanide 
• 245469-68-5 2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 154544-30-6 1-(3-methoxy-4-hydroxyethoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione 
• 154544-31-7 1-(3-methoxy-4-hydroxyethoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanediol 
• 154544-29-3 4-(2-hydroxyethoxy)-3-iodo-5-methoxybenzaldehyde 

Relevant academic research and scientific papers

PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS

A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor (“PAF”) or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C3-18 esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, containing the: active agent in crystalline form. The invention also encompasses the novel crystalline form of the active agent, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of isopropyl alcohol (IPA) to enhance stability of the active agent and pharmaceutical formulations.

Synthesis of (± )trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-cyanophenyl]-5-(3,4, 5-trimethoxyphenyl) tetrahydrofuran

The synthesis of a potent platelet activating factor is described utilising commercially available acetovanillone and ethyl 3,4,5-trimethoxybenzoylacetate.

(±)-Trans-2-[3-methoxy-4-(4-chlorophenyl thioethoxy)-5-cyanophenyl]-5- (3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent PAF-receptor antagonist

The synthesis of (±)-trans-2-[3-methoxy-4- (chlorophenylthioethoxyphenyl)-5-cyanophenyl]-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran from commercially available acetovanillone and 3,4,5-trimethoxybenzaldehyde is described.

(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.

By incorporating an N-hydroxyurea functionality onto diaryltetrahydrofurans, a novel series of compounds was investigated as dual 5-lipoxygenese (5-LO) inhibitor and platelet-activating factor (PAF) receptor antagonist. These dual functional compounds wer